Formycon
Manufacturing · Germany · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Fraunhoferstr. 15, Planegg, Bavaria, 821...Phone Number
+49 89864667100Website
www.formycon.comRevenue
$85.9 MillionStock Symbol
NNDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Formycon
Formycon AG is a global, independent developer of biosimilars, dedicated to improving patient access to high-quality, safe, and affordable biological medicines. The company focuses on creating sustainable value for investors while contributing to the growth of the biosimilars market. Formycon's sustainability strategy aims to enhance the positive impacts of its operations and effectively mitigate sustainability-related risks. Their target clients include patients in need of biologic treatments and investors seeking opportunities in the biosimilars sector.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Formycon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Formycon had a recent Job posting/layoffs
Check out if Formycon is spiking on competitors!
Funding: Get notified immidiatlly once Formycon has new funding data
Formycon, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Formycon has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Formycon
Product Launch: Get notified when Formycon launches new products
Earning: See what the market has to say on Formycon recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Formycon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Formycon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Formycon.
Formycon Tech Stack
A closer look at the technologies used by Formycon
See more technologies
Most Recent Scoops
Partnership
Formycon has announced that its partner Fresenius has secured an additional direct contract with a US federal government entity for Otulfi, expected to generate revenues from the second half of the current year, complementing an earlier direct contract with CivicaScript that significantly increased US sales in Q4 2025; both contracts are expected to deliver long-term value contributions for the product.
Partnership, Sales, Contracts
Project
Formycon has announced that its partner Sandoz re-introduced CIMERLI in the US market in January following a planned sales pause in 2025 that successfully allowed reimbursement prices to recover to a level enabling profitable commercialization, with initial post-relaunch sales described as satisfactory and volume expected to increase over the coming months.
Pharmaceuticals
Partnership
Formycon has entered into a partnership with Lotus Pharma for FYB206 in key Asian markets including South Korea, Taiwan, Vietnam, and Thailand, signed at the start of the current year, and has also selected MS Pharma as its partner for the MENA region, leveraging the firm's strong regional market presence.
Partnership
Project
Formycon has launched FYB203 simultaneously across multiple European markets on May 15, marketed under the brands AHZANTIVE and Baiama by three European partners, following patent settlements reached with Regeneron and Bayer in 2025 covering all relevant markets.
Project
Product Launch, Pharmaceuticals, Revenue Operations
Formycon News & Media
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
AHMEDABAD, India and PLANEGG-MARTINSRIED, Germany, Dec. 9, 2025 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an international presence, today announced that its wholly owned subsidiary, Zydus...Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda®1 (Pembrolizumab), in the U.S. and Canada.Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
PLANEGG-MARTINSRIED, Germany and AMMAN, Jordan, Dec. 4, 2025 /PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate...Formycon AG (FYBGF) Q3 2025 Earnings Call Transcript
Formycon AG (OTC:FYBGF) Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsStefan Glombitza - CEO, COO & Chair of the Executive...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Formycon
Sign Up For FreeTo access detailed company insights
Formycon AG is a global, independent developer of biosimilars, dedicated to improving patient access to high-quality, safe, and affordable biological medicines. The company focuses on creating sustainable value for investors while contributing to the growth of the biosimilars market. Formycon's sustainability strategy aims to enhance the positive i... Read More
